In an effort to determine if there is a specific conformational structure which is most effective at the appropriate active physiological site, the synthesis of a group of sterically restricted analogs was undertaken. A portion of the polymethylene carbon skeleton of glutaric acid was replaced by selected aromatic carbons in benzenedicarboxylic acids to produce a series of ridged conformers, and the relative plant growth regulating properties of these derivatives were determined.

Many important atmospheric processes are determined by the chemical composition of aerosols, including organic material. Dicarboxylic acids are a commonly detected class of organic material in urban, rural, and remote sites across the globe. Understanding the surface behavior of these molecules is imperative in characterizing the atmospheric fate of these molecules in aerosols, especially at an aerosol surface. In fact, little is known about their orientation, solvation, or pH dependence. This dissertation explores in molecular level detail the concentration and pH behavior of low molecular weight dicarboxylic acids at the air/water interface, which is used as a model for an aerosol surface. The solvation of the carboxylic head groups is shown to be dependent upon the length of the alkyl backbone. Indeed, the solvation of the head groups changes dramatically from very weakly solvated to typical surface solvation to near bulk solvation as the backbone increases. The orientation and conformation at the surface is fully explored to explain these differences in solvation. The pH dependence of surface adsorption is characterized, and it is shown that some acids are only surface active if they are fully protonated while others may still be surface active in singly or fully deprotonated forms. Using a combination of vibrational sum frequency spectroscopy (VSFS), surface tension, and computational modeling, the behavior at the air/water interface of four of the most relevant surface-active dicarboxylic acids (malonic, succinic, glutaric, and adipic acid) is completely described. VSFS, a surface specific optical technique, provides details about the solvation, orientation, and number density at the surface while surface tension measurements provide corollary information about the surface density. The use of computational modeling aids and confirms the spectral analysis while also providing molecular level details about the surface adsorption of the acids studied. By investigating the concentration and pH dependence of these molecules, molecular level detail is obtained which enables a complete description of these acids at an air/water interface and provides pertinent surface information on these atmospherically important organic molecules. This dissertation includes both previously published and unpublished co-authored material.

Yes / Spurred by the enormous interest in co-crystals from the pharmaceutical industry, many novel co-crystals of active pharmaceutical ingredients have been discovered in recent years and this has in turn led to an increasing number of reports on polymorphs of co-crystals. Hence, a thorough characterization and understanding of co-crystal polymorphs is a valuable step during drug development. The purpose of this study is to perform in situ structural analysis and to determine thermodynamic stability of a dimorphic co-crystal system, 1:1 caffeine-glutaric acid (CA-GA, Forms I and II). We performed thermal and structural characterizations by differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), hot-stage microscopy (HSM), slurry and in situ variable temperature X-ray diffraction (VTXRD). For completeness, we have also re-determined crystal structures of CA-GA Forms I and II at 180 K using single crystal X-ray diffraction. Our results revealed that Form II is stable and Form I is metastable at ambient conditions. Further, the results suggest that the dimorphs are enantiotropically related and the transition temperature is estimated to be 79 Celcius degrees. / This work was supported by Science and Engineering Research Council of A*STAR (Agency for Science, Technology and Research), Singapore.

Yes / Insights into structure–mechanical property correlations in molecular and multicomponent crystals have recently attracted significant attention owing to their practical applications in the pharmaceutical and specialty fine chemicals manufacturing. In this contribution, we systematically examine the mechanical properties of dimorphic forms, Forms I and II of 1:1 caffeine-glutaric acid cocrystal on multiple faces using nanoindentation to fully understand their mechanical anisotropy and mechanical stability under applied load. Higher hardness, H, and elastic modulus, E, of stable Form II has been rationalized based on its corrugated layers, higher interlayer energy, lower interlayer separation, and presence of more intermolecular interactions in the crystal structure compared to metastable Form I. Our results show that mechanical anisotropy in both polymorphs arises due to the difference in orientation of the same 2D structural features, namely the number of possible slip systems, and strength of the intermolecular interactions with respect to the indentation direction. The mechanical properties results suggest that 1:1 caffeine-glutaric acid cocrystal, metastable form (Form I) could be a suitable candidate with desired tablet performance to that of stable Form II. The overall, it demonstrates that the multiple faces of nanoindentation is critical to determine mechanical anisotropy and structure- mechanical property correlation. Further, the structural-mechanical property correlations aids in the selection of the best solid phase for macroscopic pharmaceutical formulation.

This work focuses on the physical properties and crystallization of theophyline co-crystals. Co-crystals of theophylline with oxalic acid, glutaric acid and maleic acid have been investigated. The DSC curves of these co-crystals show that their first endothermic peaks are all lower than the melting temperature of theophylline. The decomposition temperature of theophylline – oxalic acid co-crystal is at about 230 °C, determined by DSC together with TGA. After decomposition, the remaining theophylline melts at about 279 °C, which is higher than the known melting temperature of theophylline, suggesting a structure difference, ie. a new polymorph may have been formed. The formation of hydrogen bonds in theophylline – oxalic acid co-crystal was investigated by FTIR. Changes of FTIR peaks around 3120 cm-1 reflects the hydrogen bond of basic N of theophylline and hydroxyl H of oxalic acid. The solubility of theophylline – oxalic acid co-crystal and theophylline – glutaric acid co-crystal was determined in 4:1 chlroform – methanol and in pure chloroform respectively. At equilibrium with the solid theophylline – oxalic acid co-crystal, the theophylline concentration is only 60 % of the corresponding value for the pure solid theophylline. At equilibrium with the solid theophylline – glutaric acid co-crystal, the theophylline concentration is at least 5 times higher than the corresponding value for the pure solid theophylline. Two phases of theophylline were found during the solubility determination. In the chloroform – methanol mixture (4:1 in volume ratio) the solubility of the stable polymorph of theophylline is found to be about 14 % lower than that of the metastable phase. Various aspects of the phase diagram of theophylline – oxalic acid co-crystal was explored. Theophylline – oxalic acid co-crystal has been successfully prepared via primary nucleation from a stoichiometric solution mixture of the two components in chloroform – methanol mixture. By slurry conversion crystallization, the co-crystal can be prepared in several solvents, and yield and productivity can be significantly increased. Theophylline – glutaric acid can be successfully prepared via both co-grinding of the two components and slow evaporation with seeding. / QC20100608

<p>This work focuses on the physical properties and crystallization of theophyline co-crystals. Co-crystals of theophylline with oxalic acid, glutaric acid and maleic acid have been investigated.</p><p>The DSC curves of these co-crystals show that their first endothermic peaks are all lower than the melting temperature of theophylline. The decomposition temperature of theophylline – oxalic acid co-crystal is at about 230 °C, determined by DSC together with TGA. After decomposition, the remaining theophylline melts at about 279 °C, which is higher than the known melting temperature of theophylline, suggesting a structure difference, ie. a new polymorph may have been formed. The formation of hydrogen bonds in theophylline – oxalic acid co-crystal was investigated by FTIR. Changes of FTIR peaks around 3120 cm^-1 reflects the hydrogen bond of basic N of theophylline and hydroxyl H of oxalic acid. The solubility of theophylline – oxalic acid co-crystal and theophylline – glutaric acid co-crystal was determined in 4:1 chlroform – methanol and in pure chloroform respectively. At equilibrium with the solid theophylline – oxalic acid co-crystal, the theophylline concentration is only 60 % of the corresponding value for the pure solid theophylline. At equilibrium with the solid theophylline – glutaric acid co-crystal, the theophylline concentration is at least 5 times higher than the corresponding value for the pure solid theophylline. Two phases of theophylline were found during the solubility determination. In the chloroform – methanol mixture (4:1 in volume ratio) the solubility of the stable polymorph of theophylline is found to be about 14 % lower than that of the metastable phase. Various aspects of the phase diagram of theophylline – oxalic acid co-crystal was explored.</p><p>Theophylline – oxalic acid co-crystal has been successfully prepared via primary nucleation from a stoichiometric solution mixture of the two components in chloroform – methanol mixture. By slurry conversion crystallization, the co-crystal can be prepared in several solvents, and yield and productivity can be significantly increased. Theophylline – glutaric acid can be successfully prepared via both co-grinding of the two components and slow evaporation with seeding.</p> / QC20100608

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Glutaric acidemia type I (GA-I) is an inborn error of metabolism (EIM), characterized biochemically by major accumulation of glutaric acid (GA) and pathologically by a characteristic striatal degeneration. The clinical manifestations are mainly neurological and develop during childhood (up to 5 years old). Among these changes, there are the seizures and cognitive deficits, which may be precipitated by infectious processes. From this, the first hypothesis to be tested in this study was to investigate whether lipopolysaccharide E. coli 055 B5 serotype (LPS; 2 mg/Kg; i.p.), an inflammatory agent, could facilitate seizures induced by GA in young rats (21 days of life). For this, firstly it was determined the acute dose of intrastriatal GA (1.3 μmol/striatum) that cause behavioral and electroencephalographic (EEG) seizures in young rats. Moreover, it was shown that LPS administration 3 hours before GA intrastriatal injection did not change the seizures, but when LPS was administered 6 hours before the GA, it reduced the latency and increased the duration of behavioral and EEG seizures induced by GA in young rats. It also was observed that LPS injection caused an initial drop in rectal temperature of young rats (up to 2 hours), followed by a rise in temperature that started at 3 hours and remained high until 6 hours after LPS injection. Furthermore, it was shown that LPS injection 3 and 6 hours before intrastriatal injection of GA caused an increase in striatal levels of IL-1β in young rats, and this increase was statistically higher in 6 than in 3 hours. In addition, it was observed that the increase in IL-1β striatal levels, caused by LPS administration, positively correlated with total time of seizures. Finally, it was observed that previous use of IL-1β antibody prevented the latency reduction and the increased duration of seizures caused by LPS administration 6 h before intrastriatal injection of GA in young rats. Thus, these findings suggest that the signaling of IL-1β present in inflammation produced by LPS contributes significantly to neuronal hyperexcitability, and thus to reduce latency and increase the duration of seizures induced by GA. Therefore, pharmacological treatments that block the specific functions or overproduction of IL-1β in GA-I, may represent an unconventional strategy to treat this condition. However, clinical studies should be conducted to evaluate the effectiveness of treatment in glutaricoacidemic patients with convulsions. Since patients with GA-I have other important neurological changes addition to the seizures, as cognitive impairments, the second hypothesis to be tested in this study was to determine whether chronic treatment with GA (5 μmol/g; s.c.; twice per day; from the 5th to the 28th day of life) could cause spatial memory impairment in young rats, and verify whether the inflammation produced by LPS (2 mg/Kg; i.p.; one per day; from the 25th to the 28th day of life) could facilitate the cognitive deficit induced by GA. In addition, it also was evaluated the possible impact of these treatments on functional and structural changes in the hippocampus of these animals. Initially it was shown that chronic treatment with GA, as well as the treatments with LPS and GA-LPS, caused a deficit in spatial learning of young rats. However, it was demonstrated that the treatment with GA-LPS produced a greater impairment in spatial memory compared to other treatments. In addition, it was observed that none of the treatments affected weight or locomotor activity/exploratory of animals. It also was shown that chronic treatment with GA, as well as treatments with LPS and GA-LPS, increased the hippocampal levels of IL-1β and TNF-α in young rats. Furthermore, it was demonstrated that treatments with GA, LPS and GA-LPS caused a reduction in total hippocampal volume of young rats. Finally it was observed that treatments with GA, LPS and GA-LPS caused a reduction of α1 subunit activity of Na+,K+-ATPase enzyme. On the other hand, it was shown that treatments with GA and LPS caused an increase in activity of α2/3 subunits of the enzyme. Thus, only treatment with GA-LPS showed a reduction in total activity of Na+,K+-ATPase in the hippocampus of young rats. These data indicate that the impairment in spatial learning observed in rats treated with GA, LPS and GA-LPS was due to increased levels of inflammatory cytokines, the reduction in hippocampal volume and the inhibition of α1 subunit activity of Na+,K+-ATPase enzyme. However, the worsening in spatial memory observed in rats treated with GA-LPS was due to inhibition of total activity of Na+,K+-ATPase, which was specific α2/3 isoforms, since only this group showed no compensatory response the activity of these subunits. Therefore, this second part of the study showed that chronic treatment with GA caused a deficit in spatial learning in young rats, and that the presence of an inflammatory process increased the impairment in spatial memory induced by GA alone. Thus, understanding the mechanisms involved in seizures and cognitive deficits observed in patients with GA-I in the presence of an inflammatory process is important for the development of new therapies to treat this condition, as well as other diseases associated with the presence of inflammatory mediators. / A acidemia glutárica tipo I (GA-I) é um erro inato do metabolismo (EIM) caracterizada bioquimicamente pelo acúmulo principal de ácido glutárico (GA) e patologicamente por uma característica degeneração estriatal. As manifestações clínicas são predominantemente neurológicas, e desenvolvem-se principalmente na infância (até os 5 anos de idade). Entre estas alterações, destacam-se as convulsões e os déficits cognitivos, os quais podem ser precipitados por processos infecciosos. A partir disso, a primeira hipótese a ser testada neste estudo foi investigar se o lipopolissacarídeo sorotipo E. coli 055 B5 (LPS; 2 mg/Kg; i.p.), um agente inflamatório, facilitaria as convulsões induzidas pelo GA em ratos jovens. Para isso, primeiramente determinou-se a dose intraestriatal aguda de GA (1.3 μmol/estriado) que causa convulsões comportamentais e eletroencefalográficas (EEG) em ratos jovens (21 dias). Em seguida foi verificado que a administração de LPS 3 horas antes da injeção intraestriatal de GA não alterou as convulsões, mas quando o LPS foi administrado 6 horas antes do GA, ele reduziu a latência e aumentou a duração das convulsões comportamentais e EEG induzidas pelo GA em ratos jovens. Observou-se também que injeção de LPS causou uma queda inicial na temperatura retal dos ratos jovens (até 2 horas), seguida de uma elevação na temperatura que iniciou em 3 horas e permaneceu alta até 6 horas após a injeção de LPS. Além disso, foi verificado que injeção de LPS 3 e 6 horas antes da injeção intraestriatal de GA causou um aumento nos níveis estriatais de IL-1β nos ratos jovens, sendo esse aumento estatisticamente maior em 6 do que em 3 horas. Também foi observado que o aumento nos níveis estriatais de IL-1β, causado pela administração de LPS, correlacionou-se positivamente com o tempo total de convulsões. Por fim, verificou-se que uso prévio do anticorpo da IL-1β preveniu a redução da latência e o aumento da duração das convulsões causadas pela administração de LPS 6 horas antes da injeção intraestriatal de GA nos ratos jovens. Assim, estes achados sugerem que a sinalização da IL-1β presente no processo inflamatório produzido pelo LPS contribui decisivamente para a hiperexcitabilidade neuronal e, consequentemente, para a redução da latência e o aumento da duração das convulsões induzidas pelo GA. Dessa maneira, tratamentos farmacológicos específicos que bloqueiam a superprodução ou as funções da IL-1β na GA-I, podem representar uma estratégia não convencional para o tratamento dessa patologia. Entretanto, estudos clínicos devem ser realizados a fim de avaliar a eficácia desse tratamento nos pacientes glutaricoacidêmicos que apresentam convulsões. Desde que os pacientes com GA-I apresentam outras alterações neurológicas importantes além das convulsões, como prejuízos cognitivos, a segunda hipótese a ser testada neste estudo foi verificar se o tratamento crônico com GA (5 μmol/g; s.c.; duas vezes por dia; do 5° ao 28° dia de vida) causaria déficit de memória espacial em ratos jovens, bem como se a inflamação produzida pelo LPS (2 mg/Kg; i.p.; uma vez por dia; do 25° ao 28° dia de vida) facilitaria o déficit cognitivo induzido pelo GA. Além disso, também foi objetivo avaliar o impacto desses tratamentos sobre possíveis alterações funcionais e estruturais no hipocampo desses animais. Inicialmente verificou-se que o tratamento crônico com GA, assim como os tratamentos com LPS e GA-LPS, causaram um déficit no aprendizado espacial dos ratos jovens. No entanto, foi observado que o tratamento com GA-LPS produziu um maior prejuízo na memória espacial comparado com os outros tratamentos. Em seguida foi observado que nenhum dos tratamentos alterou o peso ou a atividade locomotora/exploratória dos animais. Verificou-se também que o tratamento crônico com GA, assim como os tratamentos com LPS e GA-LPS, aumentaram os níveis hipocampais de IL-1β e TNF-α nos ratos jovens. Além disso, foi observado que tratamentos com GA, LPS e GA-LPS causaram uma redução no volume hipocampal total dos ratos jovens. Finalmente verificou-se que os tratamentos com GA, LPS e GA-LPS causaram uma redução na atividade da subunidade α1 da enzima Na+,K+-ATPase. Por outro lado, foi observado que os tratamentos com GA e LPS causaram um aumento na atividade das subunidades α2/3 da enzima. Assim, somente o tratamento com GA-LPS apresentou uma redução na atividade total da enzima Na+,K+-ATPase no hipocampo dos ratos jovens. Estes dados indicam que o prejuízo no aprendizado espacial observado nos ratos tratados com GA, LPS e GA-LPS parece estar relacionado a um aumento nos níveis de citocinas inflamatórias, a uma redução no volume hipocampal e a uma inibição na atividade da subunidade α1 da enzima Na+,K+-ATPase. No entanto, o maior prejuízo na memória espacial observado nos ratos tratados com GA-LPS ocorreu devido a inibição na atividade total da enzima Na+,K+-ATPase, que foi específica das isoformas α2/3, já que somente este grupo não apresentou resposta compensatória na atividade destas subunidades. Portanto, esta segunda parte do estudo demonstrou que o tratamento crônico com GA causou um déficit no aprendizado espacial de ratos jovens, e que a presença de um processo inflamatório potencializou o prejuízo na memória espacial induzida pelo GA sozinho. Assim, o entendimento dos mecanismos envolvidos nas convulsões e no déficit cognitivo observados nos paciente com GA-I frente a um processo inflamatório é importante para o desenvolvimento de novas terapias para o tratamento dessa patologia, bem como de outras doenças associadas à presença de mediadores inflamatórios.

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior / Glutaric acidemia type I (GA-I) is an inborn error of metabolism (EIM) biochemically characterized by the main accumulation of glutaric acid (GA) and 3- hydroxyglutaric acid (3-OH-GA), and pathologically by a characteristic striatal degeneration. Due the absence of effective therapeutic strategies for this acidemia, several studies have investigated new therapies, since that one in three children subject to current treatments show striatal degeneration. In this context, the present work aimed in the first part, to investigate the effects of acute treatment with creatine (Cr), an endogenous compound guanidine which has shown neuroprotective effects in a variety of experimental models of neurodegenerative diseases and also in organic acidemias, on the GA-induced behavioral and neurochemical changes in vivo. Our results demonstrated that acute administration of Cr prevented the GA-induced behavioral and electrographic seizures, the carbonyl protein content increased and the Na+,K+-ATPase enzyme activity reduction in rats. Moreover, the Cr also protected the GA-induced sinaptossomal L-[3H]glutamate uptake reduction in vitro. As was observed in this first part, that the GA in a low concentration (10 nM) was able to reduce the L-[3H]glutamate uptake in striatal sinaptossomas of rats, and since that responsible mechanisms for striatal degeneration observed in patients are still poorly understood, we decided to evaluate in a second step, a primary action mechanism for the neurotoxic effects this low concentration of GA, which possibly may be present at the beginning of GA-I. We find that the GA reduced the L-[3H]glutamate uptake and increased the reactive species (ER) formation in sinaptossomas the striatum of rats in all times tested. Furthermore, we observed for the first time that the GA reduced the efficacy (VMax), but not the affinity (KD) of L-[3H]glutamate uptake in striatal sinaptossomas, suggesting a non-competitive inhibition. The addition of both the L-trans-pyrrolidine-2,4-dicarboxylate (PDC), a glutamate transporters inhibitor, with the GA did not alter the inhibitory effect on the of L-[3H]glutamate uptake induced by organic acid, indicating the involvement of glutamate transporters in the GA-induced uptake reduction. Since the glutamate transporters activity can be inhibited by oxidation, we show that although the antioxidant trolox protects against GA-induced ER formation increase, it did not protect against GA-induced glutamate uptake reduction in the synaptosomes of cerebral structure studied, suggesting that ER formation may be a late event in the neurotoxicity observed in GA-I. Moreover, we can not exclude the possibility that the GA may also directly stimulate the glutamate receptors, since the GA-induced ER formation was reduced by the non-NMDA glutamate receptor antagonist, the CNQX, but not by MK-801, suggesting that these receptors contributed, at least partly, to the GA-induced oxidative stress. Also determined GA, in this low concentration, did not show oxidant activity per se. Therefore, from results in this study it was observed the protective effect of Cr administration in the deleterious actions caused by the GA. Furthermore, we show for the first time that a GA low concentration cause primary excitotoxicity, and oxidative stress in brain structure predominantly affected in this disease. Therefore, we believe that this work may help explain the genesis of GA-I, as well as the development of effective adjuvant therapeutic strategies in the treatment this acidemia. / A acidemia glutárica tipo I (GA-I) é um erro inato do metabolismo (EIM) caracterizada bioquimicamente pelo acúmulo principal de ácido glutárico (GA) e ácido 3-hidroxiglutárico (3-OH-GA), e patologicamente por uma característica degeneração estriatal. Devido à escassez de medidas terapêuticas efetivas para essa acidemia, vários estudos têm investigado novas terapias, já que uma em cada três crianças submetidas aos atuais tratamentos sofre degeneração estriatal. Nesse contexto, o presente trabalho teve por objetivo em sua primeira parte, investigar os efeitos do tratamento agudo com creatina (Cr), um composto guanidínico endógeno que tem mostrado efeitos neuroprotetores em uma variedade de modelos experimentais de doenças neurodegenerativas e também em acidemias orgânicas, sobre as alterações comportamentais e neuroquímicas induzidas pelo GA in vivo. Nossos resultados demonstraram que a administração aguda de Cr preveniu as convulsões comportamentais e eletrográficas, o aumento do conteúdo de proteína carbonil e a redução da atividade da enzima Na+,K+-ATPase induzidos pelo GA em ratos. Além disso, a Cr também protegeu da redução da captação de L-[3H]glutamato sinaptossomal induzida pelo GA in vitro. Como foi observado nesta primeira parte, que o GA em uma baixa concentração (10 nM) foi capaz de reduzir a captação de L-[3H]glutamato em sinaptossomas estriatais de ratos, e desde que os mecanismos responsáveis pela degeneração estriatal observada nos pacientes glutaricoacidêmicos ainda não estão bem esclarecidos, decidimos avaliar em uma segunda etapa, um provável mecanismo de ação primário para os efeitos neurotóxicos desta baixa concentração de GA, que possivelmente pode estar presente no início da GA-I. Verificamos que o GA reduziu a captação de L-[3H]glutamato e aumentou a formação de espécies reativas (ER) em sinaptossomas de estriado de ratos em todos os tempos testados. Além disso, observamos pela primeira vez que o GA reduziu a eficácia (VMax), mas não a afinidade (KD) da captação de L-[3H]glutamato em sinaptossomas estriatais, sugerindo uma inibição do tipo não competitiva. A adição simultânea do L-trans-pirrolidina-2,4-dicarboxilato (PDC), um inibidor dos transportadores de glutamato, com o GA não alterou o efeito inibitório sobre a captação de L-[3H]glutamato induzido pelo ácido orgânico, indicando a participação dos transportadores de glutamato na redução da captação desse neurotransmissor induzida pelo GA. Desde que a atividade dos transportadores de glutamato pode ser inibida por oxidação, evidenciamos que embora o antioxidante trolox proteja do aumento da formação de ER induzidas pelo GA, ele não protege da redução da captação de L-[3H]glutamato induzida por este ácido orgânico em sinaptossomas de estriado. Estes achados sugerem que a formação de ER pode ser um evento tardio na neurotoxicidade observada na GA-I. Além disso, não podemos excluir a possibilidade de que o GA também possa estimular diretamente os receptores de glutamato, desde que a formação de ER induzidas pelo GA foi atenuada pelo antagonista de receptor de glutamato não-NMDA, o CNQX, mas não pelo MK-801 e o GA, nessa baixa concentração, não apresentou atividade oxidante per se. Portanto, os resultados apresentados no presente estudo demonstram que a administração previa de creatina protege das ações deletérias ocasionadas pelo GA. Além disso, evidenciamos, pela primeira vez, que uma baixa concentração de GA causa ações excitotóxicas primárias, bem como, estresse oxidativo na estrutura cerebral predominantemente afetada nesta doença. Assim, acreditamos que este trabalho possa auxiliar na elucidação da gênese da GA-I, bem como no desenvolvimento de estratégias terapêuticas adjuvantes eficazes no tratamento desta acidemia.

Depuis une quinzaine d’années, les polymères chiraux sont utilisés dans de nombreuses applications, comme phases stationnaires pour la séparation d’énantiomères ou encore en tant que catalyseurs en synthèse asymétrique. Aux vues de ces intérêts grandissants, de nombreuses méthodes ont émergé afin de les synthétiser. Nous nous sommes concentrés sur des méthodes organocatalytiques originales de synthèse de polymères chiraux par réaction de polyaldolisation et par désymétrisation de bis-anhydrides. Nous avons ainsi développé des processus de désymétrisation itératifs et ainsi généré une chiralité C-centrée sur la chaine polymérique. Des polyesters chiraux ont ainsi été obtenus avec de très bonnes séléctivités. / Chiral polymers are used in many applications such as stationary phases for chiral HPLC and catalysts in asymetric synthesis. The synthesis of chiral polymers traditionally deals with metal catalysts-based methodologies and often involved sensitive substrates. On the other hand, only a limited number of publications has been reported through environmentally-friendly organocatalytic pathways.The goal of this Ph.D. studies was devoted to the design of new routes toward chiral polymers under organocatalysis. We chose polyaldolisations and anhydride desymmetrizations with alcohols as key reactions to obtain original polymers with a C-centered chirality in the main polymer chain.

Monosialoganglioside (GM1) is a component of most cell membranes and is thought to play a role in development, recognition and cellular differentiation. Furthermore, GM1 is a neuroprotective agent that has been reported to scavenge free radicals generated during reperfusion and to protect receptors and enzymes from oxidative damage. In the present study we investigate the effect of GM1 on the catalase (CAT), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities, on the spontaneous chemiluminescence and total radical-trapping potential (TRAP) in cortex of rats ex vivo and in vitro. Systemic GM1 administration (50 mg/kg, i.p.; twice) reduced spontaneous chemiluminescence and increased CAT activity ex vivo. On the other hand, GM1 (103-104 nM) reduced CAT activity in vitro. The other parameters were not affected by GM1 administration. These findings agree with the view that the antioxidant action of GM1 is not due to an intrinsic antioxidant activity of this glycolipid, but due to a secondary decrease of reactive species generation and/or increase of antioxidant defenses. Moreover, we evaluated whether GM1 could have a neuroprotective action on the experimental model of glutaric acidemia, an inherited metabolic disorder characterized by glutaric acid (GA) accumulation and neurological dysfunction, as striatal degeneration and convulsion. The systemic GM1 administration (50 mg/kg, i.p. twice) protected against the convulsions, oxidative damage markers increase (total protein carbonylation and thiobarbituric acid-reactive substances - TBARS) production and Na+,K+-ATPase activity inhibition induced by GA (4 mol/ 2 l) in striatum of rats. Furthermore, convulsive episodes induced by GA strongly correlated with Na+,K+-ATPase activity inhibition in the injected striatum, but not with oxidative stress marker measures. In addition, GM1 (50-200 M) protected against Na+,K+-ATPase inhibition induced by GA (6 mM), but not against oxidative damage in vitro. Intrastriatal administration of muscimol (46 pmol/striatum), a GABAA receptor agonist, but not glutamatergic receptor antagonists MK-801 (3 nmol/striatum) and DNQX (8 nmol/striatum), prevented GA-induced convulsions and inhibition of Na+,K+-ATPase activity. The protection of GM1 and muscimol against GA-induced seizures strongly correlated with Na+,K+-ATPase activity maintenance in the injected striatum with GA. Since GM1 and muscimol prevented neurotoxic effects induced by GA, we investigated the GM1 action after intrastriatal administration of pentylenetetrazole (PTZ), a GABAA receptor antagonist. GM1 treatment prevented seizures, Na+,K+-ATPase inhibition, and increase of TBARS and protein carbonyl induced by PTZ (1.8 mol/striatum) in the rats striatum. Furthermore, these data suggest that Na+,K+-ATPase and GABAA receptor-mediated mechanisms may play important roles in GA-induced seizures and in their prevention by GM1. / O monossialogangliosídeo (GM1) é um componente natural de membrana plasmática que está envolvido no crescimento, reconhecimento e diferenciação celular, além de proteger o SNC da ação dos radicais livres. No presente estudo investigou-se o efeito do GM1 sobre a atividade das enzimas antioxidantes catalase (CAT), superóxido dismutase (SOD) e glutationa peroxidase (GPx), assim como na quimiluminescência e capacidade antioxidante total (TRAP) em córtex cerebral de ratos machos adultos ex vivo e in vitro. A administração sistêmica de GM1 (50 mg/kg, i.p.; duas doses: 24 horas e 30 minutos antes do sacrifício) reduziu a quimiluminescência e aumentou significativamente a atividade da CAT ex vivo. A adição de GM1 (103-104 nM) ao meio de incubação diminuiu a atividade da CAT in vitro. Estes resultados sugerem que o efeito neuroprotetor do GM1 não é devido à ação antioxidante intrínseca deste glicoesfingolipídeo, mas devido ao aumento secundário das defesas antioxidantes e/ou uma redução da geração de radicais livres. Além disso, avaliamos se o GM1 tinha efeito neuroprotetor em um modelo experimental da acidemia glutárica, um erro inato do metabolismo caracterizado pelo acúmulo tecidual de ácido glutárico (GA) e alterações neurológicas, como degeneração estriatal e convulsões. A administração de GM1 preveniu as convulsões, o aumento da produção dos marcadores do dano oxidativo (carbonilação protéica total e substâncias reativas do ácido tiobarbitúrico - TBARS) e a inibição da atividade da Na+,K+-ATPase induzidas pelo GA (4 mol/2 µl) em estriado de ratos. Além disso, os episódios convulsivos induzidos por GA apresentaram uma correlação significativa com a inibição da atividade da Na+,K+-ATPase no estriado injetado, mas não com os níveis dos marcadores do estresse oxidativo. A adição de GM1 (50 200  ao meio de incubação preveniu a inibição da Na+,K+-ATPase, mas não reduziu o dano oxidativo induzido por GA (6 mM) in vitro. A administração intraestriatal de muscimol (46 pmol/0,5 l), um agonista de receptor GABAA, mas não dos antagonistas de receptores glutamatérgicos, MK-801 (3 nmol/0,5 l) e DNQX (8 nmol/0,5 l), preveniu as convulsões e a inibição da atividade da Na+,K+-ATPase induzidas por GA. A proteção do GM1 e muscimol contra as convulsões induzidas por GA apresentou uma correlação significativa com a manutenção da atividade da Na+,K+-ATPase no estriado injetado com GA. Desde que o GM1 e o muscimol preveniram os efeitos neurotóxicos induzidos pelo GA, investigou-se a ação do GM1 após a administração intraestriatal de pentilenotetrazol (PTZ), um antagonista de receptores GABAA. O tratamento com GM1 preveniu as convulsões, o dano oxidativo e a inibição da atividade da Na+,K+-ATPase induzidas por PTZ (1,8 µmol/2 µl). Esses dados sugerem que a atividade da Na+,K+-ATPase e mecanismos mediados pela ativação de receptores GABAérgicos podem ser de grande importância para a atividade convulsiva induzida por GA, bem como nos mecanismos de neuroproteção induzidos pelo GM1.